Agenus Stock Price. Everything You Need To Know About The Agenus Stock!
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 533 full-time employees. The company went IPO on 2000-02-04. The firm is focused on the discovery and development of therapies that engage the body’s immune system to fight cancer and infections. The Company’s I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy and vaccine adjuvants. The Company’s antibody candidates are botensilimab (a CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Botensilimab is in three Phase 2 studies as a monotherapy (melanoma), in combination with chemotherapy (pancreatic cancer), and in combination with balstilimab (microsatellite stable colorectal cancer (MSS CRC)). Its clinical-stage portfolio also includes Botensilimab (AGEN1181), Balstilimab (AGEN2034), Zalifrelimab (AGEN1884), AGEN2373, AGEN1423, AGEN1571, MK-4830, INCAGN1876, INCAGN2390, INCAGN2385, BMS-986442, UGN-301, agenT-797 and QS-21 STIMULON. AGEN2373, a CD137 monospecific antibody in a Phase 1b clinical trial.
Agenus Stock Price. Everything You Need To Know About The Agenus Stock! performance
- Employees 533
- Company HQ Lexington
- Website https://agenusbio.com/
- AGEN Asset Type Common Stock
- AGEN Market Capitalization 267.3M
- Earnings Per Share -13.8
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam with a keen interest in the stock market? Look no further than Agenus, a promising stock that deserves your attention. As a content marketing expert at Zorion, we understand the importance of making informed investment decisions. Agenus is a biotechnology company specializing in the discovery and development of innovative cancer treatments. With a strong portfolio of oncology candidates in clinical trials, Agenus has the potential for substantial growth. Investing in Agenus from Malaysia, Thailand, Indonesia, or Vietnam is now easier than ever. Zorion offers comprehensive investment insights and recommendations, as well as educational resources to enhance your investment knowledge. Start your journey towards financial success by investing in Agenus today.
